Carcinoid syndrome comprises of signs and symptoms such as flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are developed secondary to carcinoid tumor. The term ‘carcinoid crisis’ is used when all the symptoms of carcinoid syndrome show at a time. Carcinoid tumors arise out of neuroendocrine cells which are present all over the human body and most commonly occur at stomach, small intestine, colon, appendix or lungs and rarely in pancreas, testicle and ovaries. However, carcinoid syndrome may also arise due to cause other than carcinoid tumor. Patient has to seek symptomatic treatment for carcinoid syndrome and there is no cure for the symptoms of carcinoid tumor.
If carcinoid tumor is not detected, carcinoid syndrome can be undiagnosed as its symptoms resemble to those of asthma, irritable bowel disease and menopause. However, patient often receives delayed treatment for carcinoid syndrome as tumors do not show significant symptoms until they are not confined to small bowel or other site of tumor origin. The management of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor. Some of the commercially available chemotherapeutic agents for management of carcinoid syndrome include Sandostatin (Novartis AG), Somatuline Depot (Ipsen Biopharmaceuticals, Inc.) etc.
Request For Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3539
The primary factor driving the growth of global carcinoid syndrome market is incidence of carcinoid tumor. As per National Institute of Health statistics, worldwide incidence of carcinoid tumor is 2 per 100,000 person with high incidence of GI carcinoid tumors. Every year over 8,000 patients in the U.S are diagnosed with carcinoid tumor in GI tract. Other factors influencing the global carcinoid syndrome management market include increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. The only factor restraining the growth of global carcinoid syndrome management market is no availability of drugs approved to manage carcinoid syndrome.
Geographically, carcinoid syndrome management market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to be the leader in global carcinoid syndrome management market owing to increasing caseload of carcinoid tumor in the U.S. The market in Asia Pacific and Japan is expected to grow at significant CAGR due to availability of generic formulations of innovator drugs in these regions. Europe is expected to take second largest share in the global carcinoid syndrome management market.
Carcinoid Syndrome Management Market: Key PlayersSome of the major players in the global carcinoid syndrome management market are Novartis International AG (Sandoz), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Biopharmaceuticals, Inc., Sirtex Medical Limited, BTG International Ltd. among others. Companies that provide generic chemotherapeutic agents include Wockhardt Ltd., Sun Pharmaceutical Industries Limited, Sagent Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd. etc.
Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-3539